UNSPSC 51413506: Tadalafil

This classification denotes a cgmp phosphodiesterase inhibitor with the molecular formula C22H19N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 742SXX0ICT, chemically known as pyrazino(1,2:1,6)pyrido(3,4-b)indole-1,4-dione,6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6r-trans)- but generally known as tadalafil, which bears US NIH Compound Identifier 110635. European Medicines Agency schedules Tadalafil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12602MIG.

UNSPSC 51413506 Tadalafil is a Commodity code representing individual pharmaceutical products procured by state and local health agencies, emergency services, and multi-state cooperative purchasing alliances for clinical use. State and local governments buying under this code are acquiring specific branded and generic medications for emergency medical services, state health programs, and institutional pharmacy networks. The City of Tampa's Fire Rescue procurement exemplifies the typical scope—sealed bids for advanced life support medications with firm pricing, expiration-date warranties, rapid delivery cycles, and 365-day defect warranties. The issuing bodies span municipal fire departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) demonstrates the multi-state scope of institutional pharmaceutical procurement, while the Texas Health and Human Services Commission's exploratory RFI shows state-level interest in direct-to-manufacturer pharmacy programs.

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications with a response deadline of April 8, 2026, and an estimated contract value of $40,000, requiring delivery within ten calendar days with a one-year term and renewal options. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802, due March 26, 2026, to establish multi-vendor contracts for generic pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026, requiring manufacturers to maintain relationships with authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards.